Mov Disord. 2003 Jul;18(7):738-50. doi: 10.1002/mds.10473.
The Movement Disorder Society Task Force for Rating Scales for Parkinson's Disease prepared a critique of the Unified Parkinson's Disease Rating Scale (UPDRS). Strengths of the UPDRS include its wide utilization, its application across the clinical spectrum of PD, its nearly comprehensive coverage of motor symptoms, and its clinimetric properties, including reliability and validity. Weaknesses include several ambiguities in the written text, inadequate instructions for raters, some metric flaws, and the absence of screening questions on several important non-motor aspects of PD. The Task Force recommends that the MDS sponsor the development of a new version of the UPDRS and encourage efforts to establish its clinimetric properties, especially addressing the need to define a Minimal Clinically Relevant Difference and a Minimal Clinically Relevant Incremental Difference, as well as testing its correlation with the current UPDRS. If developed, the new scale should be culturally unbiased and be tested in different racial, gender, and age-groups. Future goals should include the definition of UPDRS scores with confidence intervals that correlate with clinically pertinent designations, "minimal," "mild," "moderate," and "severe" PD. Whereas the presence of non-motor components of PD can be identified with screening questions, a new version of the UPDRS should include an official appendix that includes other, more detailed, and optionally used scales to determine severity of these impairments.
帕金森病评定量表运动障碍协会特别工作组对统一帕金森病评定量表(UPDRS)进行了批评。UPDRS的优点包括广泛应用、适用于帕金森病临床全谱、几乎全面涵盖运动症状以及具有测量学特性,包括信度和效度。缺点包括书面文本中的若干模糊之处、对评估者的指导不足、一些度量缺陷以及缺乏关于帕金森病几个重要非运动方面的筛查问题。特别工作组建议运动障碍协会(MDS)赞助开发新版UPDRS,并鼓励努力确定其测量学特性,特别是满足定义最小临床相关差异和最小临床相关增量差异的需求,以及测试其与当前UPDRS的相关性。如果开发出新量表,应无文化偏见,并在不同种族、性别和年龄组中进行测试。未来目标应包括定义与临床相关指定“轻度”“中度”和“重度”帕金森病相关的带有置信区间的UPDRS分数。鉴于帕金森病非运动成分的存在可通过筛查问题识别,新版UPDRS应包括一个官方附录,其中包含其他更详细且可选择使用的量表,以确定这些损伤的严重程度。